Herpes

Product Candidate Description

This single molecule has been used by Beech Tree's physicians and veterinarians to address all herpes infections of man and animals. Diseases responding to this approach include herpes simplex types I and II, herpes zoster (chickenpox), shingles, infectious mononucleosis, cytomegalovirus, and Bell’s palsy. Also, herpes infections of dogs and horses also respond quickly.

With a third of the world’s human population expected to suffer a herpes infection this year, the market for a safe product that can be used at the same dose for any such infection is extraordinary.

Laboratory Status

In vitro work conducted by company scientists has show results suggesting that this product inhibits re-assembly of virus particles after infection of cells and virus uncoating. Confirmatory work has yet to be completed. On-going genomics studies are revealing mechanism of action.

Clinical Status

Anecdotal experience by practitioners in the Beech Tree Labs' network indicate that this product candidate induces responses quickly and completely. No adverse effects have been reported.

Path Forward

A FDA-authorized, Phase 1/2a clinical trial is in progress.